Project Grant R01CA300078
Award Date 4/2/26
Completion Date 3/31/31
Dollars Obligated $646K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Emory University a $156,500 Project Grant on August 1, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct integrated multi-omics research exploring the pathophysiology of cachexia in head and neck squamous cell carcinoma (HNSCC) patients. The two-year project, concluding July 31, 2027, will investigate the systemic biological mechanisms underlying cancer cachexia through comprehensive analysis of...
- Federal Grant Award Summary The National Cancer Institute awarded Emory University a $402,401 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on April 6, 2026, with completion scheduled for March 31, 2028. This research initiative focuses on developing sex-specific immunotherapeutic approaches to overcome resistance to immune checkpoint inhibitors (ICI) in pancreatic ductal adenocarcinoma (PDAC). The project delivers integrated research services encompassing basic and...
- Federal Project Grant Award Summary Emory University received a $158,899 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded June 20, 2025, with completion targeted for May 31, 2027. This award supports the development of an innovative Simultaneous Intensity Energy Modulation and Compensation (SIEMAC) optimization platform and integrated quality assurance (QA) system for conformal flash proton therapy treatment of central lung...
- Federal Grant Award Summary Emory University received a $1.42M Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2025, through March 31, 2030. This R01 research grant supports a translational research initiative investigating neoadjuvant combination immunotherapy for melanoma treatment. The research team, led by Dr. Paulos (T cell immunologist) and Dr. Lesinski (translational scientist), will conduct...
- Federal Project Grant Award Summary New York University School of Medicine received a $315,246 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective August 1, 2025, through July 31, 2030. This five-year research initiative, titled "Breaking Cytokine Loops in Lung Adenocarcinoma," will deliver fundamental cancer research and scientific investigation focused on understanding immune resistance mechanisms in lung cancer...
- Federal Grant Award Summary The National Cancer Institute awarded Yale University a $478,532 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This research initiative will investigate the biological and clinical significance of spatial immune heterogeneity in non-small cell lung cancer (NSCLC), with particular focus on characterizing how the spatial distribution of tumor-infiltrating lymphocytes (TILs) and tertiary...
- Federal Project Grant Award Summary National Jewish Health received a $435,062 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2028. The award funds fundamental research investigating how myelodysplastic syndrome (MDS)-associated mutations in the spliceosome impair Natural Killer (NK) cell function. The research deliverables include mechanistic characterization of cellular and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Beckman Research Institute of the City of Hope a Project Grant totaling $733,864 under the Cancer Biology Research program (CFDA 93.396) for the period June 1, 2026 through May 31, 2031. This award funds fundamental research aimed at identifying and characterizing stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR), a critical mechanism of tumor surveillance and...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $680,121 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. This award supports fundamental research to understand the immunoevasion mechanisms employed by precancerous stem cells in basal-like breast cancer (BLBC), with the goal of developing immunoprevention strategies to intercept progression to aggressive...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $472,730 project grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025, through July 31, 2030. This five-year project investigates the role of the tumor suppressor KEAP1 (Kelch-like ECH-associated protein 1) in antitumor immunity, with specific focus on understanding how loss-of-function KEAP1 mutations contribute to immune...